Results 1 to 10 of about 7,937 (220)
Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges
Journal of Public Health and Primary Care, 2021 Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type
Sweety Sharma, Bhawna Sharma
doaj +2 more sources
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis [PDF]
JACC: Basic to Translational Science, 2019 Summary: Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue.
Kathleen W. Zhang, MD +2 more
doaj +3 more sources
Multiple Red Flags of Transthyretin Amyloid Cardiomyopathy in a Single Patient: A Case Report on Diagnostic Challenge [PDF]
International Medical Case Reports JournalLingling Yao,1,* Kexin Chen,1,* Fusheng Zhang,1 Jun Qin2 1Cardiac Care Unit, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, People’s Republic of China; 2Department of Hematopathology, Renmin Hospital, Hubei University of ...
Yao L, Chen K, Zhang F, Qin J
doaj +2 more sources
Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy [PDF]
Cardiology and TherapyTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by the deposition of insoluble amyloid fibrils derived from misfolded transthyretin (TTR).
Emily Margolin +5 more
doaj +2 more sources
Stem Cell Research, 2023 Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease caused by the abnormal production of misfolded TTR protein by liver cells, which is then released systemically.
Pilar Montero-Calle +14 more
doaj +1 more source
AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods
Терапевтический архив, 2021 There are presented the literature data and a description of the clinical course of the disease in isolated/predominant cardiac amyloidosis. Amyloid cardiomyopathy is the most common phenocopy of hypertrophic cardiomyopathy.
Alexandra Ya. Gudkova +13 more
doaj +1 more source
A new era in treatment of cardiac amyloidosis: an overview of the Congress of cardiology
Лечащий Врач, 2022 Amyloidosis is a group of diseases characterized by accumulation of a protein of a specific fibrillar structure in the interstitium of various organs and tissues.
I. E. Strelkova
doaj +1 more source
Nature Communications, 2021 Transthyretin amyloid cardiomyopathy is a treatable but often unrecognized cause of heart failure. We derived and validated a machine learning model based on medical diagnostic codes that identifies heart failure patients at risk for wild-type ...
Ahsan Huda +9 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Several imaging parameters and biomarkers provide diagnostic and prognostic information for wild‐type transthyretin amyloid cardiomyopathy.
Mami Morioka +13 more
doaj +1 more source
A review of transthyretin cardiac amyloidosis
Romanian Journal of Internal Medicine, 2023 Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global
Jhawar Nikita +2 more
doaj +1 more source